The Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric Varices
Post-balloon Occluded Retrograde Transvenous Obliteration Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric Varices
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Chengdu, China
- Recruiting
- West China Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of liver cirrhosis
- Clinical diagnosis of isolated gastric varices
- The presenec of spontaneous portosystemic shunt
Exclusion Criteria:
- Contradictions to Propranolol
- Balloon occluded retrograde transvenous obliteration was failed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Propranolol group
Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
|
Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
|
|
No Intervention: control group
Propranolol was not given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Worsening of esophageal varices rate
Time Frame: 3 years
|
Analysis
|
3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variceal rebleeding rate
Time Frame: 3 years
|
Analysis
|
3 years
|
|
Mortality rate
Time Frame: 3 years
|
Analysis
|
3 years
|
|
Worsening of ascites rate
Time Frame: 3 years
|
Analysis
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Gastrointestinal Diseases
- Liver Diseases
- Fibrosis
- Esophageal Diseases
- Liver Cirrhosis
- Esophageal and Gastric Varices
- Hypertension, Portal
- Varicose Veins
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Propranolol
Other Study ID Numbers
Other Study ID Numbers
- Propranolol in GV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Portal Hypertension
-
NCT04007289Active, not recruitingIntrahepatic Non Cirrhotic Portal Hypertension
-
NCT07304466RecruitingLiver Transplantation | Portal Hypertension
-
NCT07419724RecruitingPortal Hypertension | Variceal Bleeding
-
NCT06797193Recruiting
-
NCT03436550CompletedPortal Hypertension | Clinically Significant Portal Hypertension
-
NCT02635815Completed
-
NCT06015373CompletedClinically Significant Portal Hypertension
-
NCT01714609CompletedClinically Significant Portal Hypertension
-
NCT07473375RecruitingCirrhosis | Portal Vein Thrombosis | Portal Hypertension, Noncirrhotic | Portal Hypertension Related to Cirrhosis
-
NCT07358663RecruitingPortal Hypertension | Esophagogastric Varices
Clinical Trials on Propranolol
-
NCT07560332Completed
-
NCT01988831SuspendedStage IB Skin Melanoma | Stages III Skin Melanoma | Stages II Skin Melanoma
-
NCT01069159UnknownPosttraumatic Stress Disorder | Traumatic Memory
-
NCT07528235Not yet recruitingIntracerebral Hemorrhage | Stroke-Associated Pneumonia (SAP)
-
NCT02268357Completed
-
NCT03152175RecruitingTrauma and Stressor Related Disorders | Post-traumatic Stress Disorders | Adjustment Disorders | Acute Stress Disorder
-
NCT04074473UnknownCirrhosis | Acute Kidney Injury | Esophageal Varices
-
NCT01175538UnknownHepatic Encephalopathy